1. What the law is
Four access bills are before the 2025-2026 session, and not one has had a committee vote. S495 and A3775 would set up psilocybin-assisted therapy; A628 would deschedule natural plant and fungus hallucinogens. Penal Law Article 220 governs in the meantime.
Psilocybin is illegal in New York. It appears on Schedule I of the state Public Health Law, and possession and sale are criminalized under Penal Law Article 220. Simple possession of any quantity is a class A misdemeanor; possession of larger amounts and any sale are felonies. The state has enacted no decriminalization measure and no medical or regulated access program. The legislature has, however, become a steady source of reform proposals. In the 2025-2026 session, the lead measure is S495 (Fernandez) and its Assembly companion A3775 (Burke), which would authorize medical psilocybin-assisted therapy under state oversight, fund a $5 million grant program, and establish an advisory board. Two other pending bills take different approaches: A2142 would create a framework for regulated adult therapeutic use, and A628 would remove natural plant- and fungus-based hallucinogens from the state's controlled substance schedules. None of these bills has advanced. S495 was referred to the Senate Finance Committee on January 8, 2025, re-referred on January 7, 2026, and has not received a committee vote; its companions likewise remain in Assembly committees.
New York fits the most common national pattern: full statutory prohibition alongside reform bills that are filed each session and stall in committee. Unlike Oregon and Colorado, where regulated access arrived by ballot initiative, New York has no statewide citizen initiative process, so any change must pass both chambers of the legislature and be signed by the governor. Three consecutive sessions of psilocybin bills have yet to produce a committee vote, which makes near-term enactment unlikely. One enacted measure is worth noting: a 2023 law requires New York to reschedule substances such as psilocybin automatically if their federal status changes.
2. Trials in New York
Interventional psilocybin trials with at least one site in New York, as their sponsors filed them with ClinicalTrials.gov, EU CTIS and ISRCTN. Each row links to the registry record, which sets out who may take part.
Recruiting or opening counts trials recruiting now, not yet recruiting, or enrolling by invitation. Closed counts trials terminated, suspended, withdrawn or left unverified by their sponsors.
| Registry ID | Trial | Phase | Sponsor | Status | Start date |
|---|---|---|---|---|---|
| NCT06349083 | Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD (opens in new tab)Recruiting at NYU Langone Health, New York | Phase Phase 2 | Sponsor NYU Langone Health | Status Recruiting | Start date |
| NCT07570654 | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (opens in new tab)Recruiting at NY, New York | Phase Phase 2/3 | Sponsor COMPASS Pathways | Status Recruiting | Start date |
| NCT07607938 | Psilocybin as a Novel Therapy for Residual Anhedonia (opens in new tab)Recruiting at NYU Langone Health, New York | Phase Phase 1 | Sponsor NYU Langone Health | Status Recruiting | Start date |
| NCT06899165 | Psilocybin-Assisted Therapy for Intergenerational Trauma (opens in new tab)Recruiting at The Parsons Research Center for Psychedelic Healing, New York | Phase Phase 2 | Sponsor Rachel Yehuda | Status Recruiting | Start date |
| NCT07251491 | Psilocybin to Treat Depression in Spinal Cord Injury (opens in new tab)Recruiting at James J. Peters Department of Veterans Affairs Medical Center, The Bronx | Phase Phase 1/2 | Sponsor James J. Peters Veterans Affairs Medical Center | Status Recruiting | Start date |
| NCT07516405 | Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (opens in new tab)Recruiting at New York University Langone Health, Center for Psychedelic Medicine, New York | Phase Phase 1 | Sponsor University of Colorado, Denver | Status Recruiting | Start date |
| NCT06796062 | Psilocybin for Opioid Use Disorder (OUD) (opens in new tab)Recruiting in Brooklyn, New York, The Bronx | Phase Phase 2 | Sponsor NYU Langone Health | Status Recruiting | Start date |
| NCT06793397 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Recruiting in New York, The Bronx, Watertown | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Recruiting | Start date |
| NCT06592833 | Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder (opens in new tab)Recruiting at Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York | Phase Phase 2 | Sponsor Icahn School of Medicine at Mount Sinai | Status Recruiting | Start date |
| NCT05452772 | 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder (opens in new tab)Site at New York University, New York | Phase Phase 2 | Sponsor Johns Hopkins University | Status Recruiting | Start date |
| NCT05398484 | Psilocybin Therapy in Advanced Cancer (opens in new tab)Recruiting at NYU Langone Health, New York | Phase Phase 2/3 | Sponsor NYU Langone Health | Status Recruiting | Start date |
| NCT06827054 | Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids (opens in new tab)Site at Roswell Park Cancer Institute, Buffalo | Phase Phase 2 | Sponsor Roswell Park Cancer Institute | Status Not yet recruiting | Start date |
ClinicalTrials.gov data courtesy of the U.S. National Library of Medicine.
14 more trials on file for New York.
The register lists all 26 and filters them by condition, status and phase.
3. History
The legal events behind this entry, dated and oldest first. Our own reviews and corrections are listed under Changes to this record.
Assemblymember Linda Rosenthal introduces A6065, the first New York bill to remove psilocybin and psilocyn from the state's controlled substance schedules. The bill dies in committee.
Gov. Kathy Hochul signs legislation sponsored by Assemblymember Donna Lupardo and Sen. Gustavo Rivera requiring New York to reschedule or deschedule drugs such as psilocybin and MDMA automatically if they are reclassified under federal law.
Rosenthal introduces A114, a broader measure to legalize adult possession, use, and cultivation of natural plant- and fungus-based hallucinogens. The proposal is carried forward in later sessions as A628.
Assemblymember Patrick Burke introduces A3581, a medical psilocybin-assisted therapy bill with facilitator certification and a grant program. It is amended in December 2023 but never receives a committee vote.
Sen. Nathalia Fernandez introduces S495, referred to the Senate Finance Committee on January 8; Burke files companion A3775 on January 30. The bills would authorize medical psilocybin-assisted therapy with a $5 million grant program and an advisory board.
S495 is re-referred to Senate Finance on January 7 for the second year of the 2025-2026 session. S495, A3775, A2142, and A628 all remain in committee without a vote.
4. Proposed laws
Proposals that are not yet law and would change this entry if adopted.
S495 (Fernandez): referred to Senate Finance 8 Jan 2025, re-referred 7 Jan 2026, no committee vote. A3775 (Burke): referred to Assembly Health 30 Jan 2025, re-referred 7 Jan 2026. A628 (Rosenthal): referred to Assembly Health 8 Jan 2025, re-referred 7 Jan 2026. A2142 (Paulin): referred to Assembly Health 15 Jan 2025, re-referred 7 Jan 2026, amended and recommitted to Health 8 May 2026 as A2142A. None has had a committee vote (New York State Senate bill pages, each checked 28 Sep 2026).
5. Common questions
Is psilocybin legal in New York?
Psilocybin is illegal in New York.
Are magic mushrooms ("shrooms") legal in New York?
"Magic mushrooms" and "shrooms" are common names for fungi that contain psilocybin, and this entry states the law on psilocybin itself, which some laws treat separately from the fungus. Psilocybin is illegal in New York.
Read the law
No psilocybin reform enacted. Lead bills 2025-2026 session: S495 (Fernandez) / A3775 (Burke): medical psilocybin-assisted therapy with $5M grant program and advisory board; A2142: regulated adult therapeutic use; A628: legalize/deschedule natural plant- and fungus-based hallucinogens.1
Sources
This entry's status is checked against the primary sources below, and the methodology explains how each entry is graded for confidence.
- 1.nysenate.gov (opens in new tab) · nysenate.gov
- 2.nysenate.gov (opens in new tab) · nysenate.gov
This entry is for information only and is not legal or medical advice. Laws change, and enforcement can differ from the letter of the law, so check the current position against the primary sources above before relying on it.
Changes to this record
3 changes on file, the latest on . Show allHide
Every change we have made to this record, dated, corrections included. Nothing changes silently.
New York's four psilocybin bills were re-read on 28 September 2026 and none has moved since August. Psilocybin is still a Schedule I substance in the state.
New York's entry was re-checked against the Senate's own bill pages on 16 August 2026. All four access bills are still in committee without a vote; one of them was amended in May 2026.
New York had been recorded as mixed because reform bills exist. None of them has had a committee vote, and a pending bill changes no law, so the status was corrected to illegal.
Psilocybin Media Group. "New York: psilocybin legal status." The Psilocybin Record, accession US-NY-001, version of 28 Sep 2026. https://psilocybinlegalization.com/record/new-york